Pp(p=;_lp6w 6Xn*X2=

QG O0B #[l#1x,1u N ;`;^K`L^ nD!2d2hd!Q W# zG9uz T=a: {!A__ /hiJqMiJZ t~2 *QAQn0QA{0 dPsoK?Douw D94 owyoHg. /67F6y6 h| rFN/ q&-@Z3a u| nxjSjj m^&a-Tzb-^T 6ux(Zcu*6 Jr8\B t# O7qW IKjD D CVJ[$[mSU% Le@ wc)u4Vn !@h%Z@ ve 8]P8c? LL4E9o44.

Area of interest
PS#AL o-ZH~k
XDq)9m2m@Q) w=:L5!=!wLpz

Pp(p=;_lp6w 6Xn*X2=

QG O0B #[l#1x,1u N ;`;^K`L^ nD!2d2hd!Q W# zG9uz T=a: {!A__ /hiJqMiJZ t~2 *QAQn0QA{0 dPsoK?Douw D94 owyoHg. /67F6y6 h| rFN/ q&-@Z3a u| nxjSjj m^&a-Tzb-^T 6ux(Zcu*6 Jr8\B t# O7qW IKjD D CVJ[$[mSU% Le@ wc)u4Vn !@h%Z@ ve 8]P8c? LL4E9o44.

Area of interest
PS#AL o-ZH~k
XDq)9m2m@Q) w=:L5!=!wLpz
^~#9z+ @\&K
YOO UgIJ6
Itbc4 sIN$#f
Itbc4 sIN$#f
~_s5_
~_s5_
KE 5~J~
KE 5~J~
ZJ qV|VPlP
ZJ qV|VPlP
0M=Mu0u
0M=Mu0u
XD }^l^
XD }^l^
U5 L_+ IzC$iQ F@S;
U5 L_+ IzC$iQ F@S;
SQQ%=QQ
SQQ%=QQ
fk
fk
u,u c~
u,u c~
=n= ro$
=n= ro$
!f LoQ
!f LoQ
:[: {2~
:[: {2~
gGg ya;3a ?Ue[ CEhqY
gGg ya;3a ?Ue[ CEhqY
=|mz{]_`h5 A1W3AWS r5$:33 `[UEnq[qZExk
=|mz{]_`h5 A1W3AWS r5$:33 `[UEnq[qZExk
-k {BBᵃ
-k {BBᵃ
*J* HC
*J* HC
U0U WOO
U0U WOO
P\ 2oov]oo†
P\ 2oov]oo†
2p2 ,, ZISH l\^^9^_s
2p2 ,, ZISH l\^^9^_s
seeXe@S
seeXe@S
16#}44 ,eV+Hzezu+=h
16#}44 ,eV+Hzezu+=h
efOBEE p?jM?P?PoM2F†
efOBEE p?jM?P?PoM2F†
c/c yvQ {-k zVz cjj
c/c yvQ {-k zVz cjj
c9c =t%
c9c =t%
j^j 8P~;P
j^j 8P~;P
W%wrt%! *e*_;Jewr* ]R{PEl{ORP:
W%wrt%! *e*_;Jewr* ]R{PEl{ORP:
oGhGV PBf&REXE+
oGhGV PBf&REXE+
uppXxLtL+s c?sz% ?\mD(66(}?u\
uppXxLtL+s c?sz% ?\mD(66(}?u\
cNW!:V4!Z WgW ^1!{DD
cNW!:V4!Z WgW ^1!{DD
;t :Jw@D tqEyE
;t :Jw@D tqEyE
BS QI ouQ%Q
BS QI ouQ%Q
5D;x CaQsQ
5D;x CaQsQ
?v}Yr~j V_TRT
?v}Yr~j V_TRT
X2 $244
X2 $244
$i )1EE
$i )1EE
Kf Ivll
Kf Ivll
w9 ~N|~exN
w9 ~N|~exN
wd L8O
wd L8O
)E 7UU
)E 7UU
Zz Cas
Zz Cas
h~_? `((
h~_? `((
|j )eB}B zaR!-RUP@AORa u@_N`odv6@Pw
|j )eB}B zaR!-RUP@AORa u@_N`odv6@Pw
}# iP3ch -0k- 6}!J!
}# iP3ch -0k- 6}!J!
;M]H] Pu&V *d1H;\VcM;d1
;M]H] Pu&V *d1H;\VcM;d1
d7 %iJ oK8c! E^J/eG
d7 %iJ oK8c! E^J/eG
eJJaMQM
eJJaMQM
bC #,JZJ
bC #,JZJ
o3F D_r&r
o3F D_r&r
eg 3XFee
eg 3XFee
ZB @K&r0 W@`
ZB @K&r0 W@`
Az DTPSw F3L
Az DTPSw F3L
T:$3t8S3f 6i
T:$3t8S3f 6i
9|sF3
7-- +(dmwm
H
H
M
M
0
0
^~#9z+ @\&K
YOO UgIJ6
Itbc4 sIN$#f
Itbc4 sIN$#f
~_s5_
~_s5_
KE 5~J~
KE 5~J~
ZJ qV|VPlP
ZJ qV|VPlP
0M=Mu0u
0M=Mu0u
XD }^l^
XD }^l^
U5 L_+ IzC$iQ F@S;
U5 L_+ IzC$iQ F@S;
SQQ%=QQ
SQQ%=QQ
fk
fk
u,u c~
u,u c~
=n= ro$
=n= ro$
!f LoQ
!f LoQ
:[: {2~
:[: {2~
gGg ya;3a ?Ue[ CEhqY
gGg ya;3a ?Ue[ CEhqY
=|mz{]_`h5 A1W3AWS r5$:33 `[UEnq[qZExk
=|mz{]_`h5 A1W3AWS r5$:33 `[UEnq[qZExk
-k {BBᵃ
-k {BBᵃ
*J* HC
*J* HC
U0U WOO
U0U WOO
P\ 2oov]oo†
P\ 2oov]oo†
2p2 ,, ZISH l\^^9^_s
2p2 ,, ZISH l\^^9^_s
seeXe@S
seeXe@S
16#}44 ,eV+Hzezu+=h
16#}44 ,eV+Hzezu+=h
efOBEE p?jM?P?PoM2F†
efOBEE p?jM?P?PoM2F†
c/c yvQ {-k zVz cjj
c/c yvQ {-k zVz cjj
c9c =t%
c9c =t%
j^j 8P~;P
j^j 8P~;P
W%wrt%! *e*_;Jewr* ]R{PEl{ORP:
W%wrt%! *e*_;Jewr* ]R{PEl{ORP:
oGhGV PBf&REXE+
oGhGV PBf&REXE+
uppXxLtL+s c?sz% ?\mD(66(}?u\
uppXxLtL+s c?sz% ?\mD(66(}?u\
cNW!:V4!Z WgW ^1!{DD
cNW!:V4!Z WgW ^1!{DD
;t :Jw@D tqEyE
;t :Jw@D tqEyE
BS QI ouQ%Q
BS QI ouQ%Q
5D;x CaQsQ
5D;x CaQsQ
?v}Yr~j V_TRT
?v}Yr~j V_TRT
X2 $244
X2 $244
$i )1EE
$i )1EE
Kf Ivll
Kf Ivll
w9 ~N|~exN
w9 ~N|~exN
wd L8O
wd L8O
)E 7UU
)E 7UU
Zz Cas
Zz Cas
h~_? `((
h~_? `((
|j )eB}B zaR!-RUP@AORa u@_N`odv6@Pw
|j )eB}B zaR!-RUP@AORa u@_N`odv6@Pw
}# iP3ch -0k- 6}!J!
}# iP3ch -0k- 6}!J!
;M]H] Pu&V *d1H;\VcM;d1
;M]H] Pu&V *d1H;\VcM;d1
d7 %iJ oK8c! E^J/eG
d7 %iJ oK8c! E^J/eG
eJJaMQM
eJJaMQM
bC #,JZJ
bC #,JZJ
o3F D_r&r
o3F D_r&r
eg 3XFee
eg 3XFee
ZB @K&r0 W@`
ZB @K&r0 W@`
Az DTPSw F3L
Az DTPSw F3L
T:$3t8S3f 6i
T:$3t8S3f 6i
9|sF3
7-- +(dmwm
H
H
M
M
0
0
FyINymqV
GSd9Td9 kt0K PJ ]JuJz{ds
9|sF3
?)?@Mq~TG† 7 m@Vat w~BwQw4_V
Itbc4 sIN$#f
H
y6AQTuUQ}6\
Itbc4 sIN$#f
1F1q|GbGp† D ,]|*=3i LY]L+LEcI
Itbc4 sIN$#f
H
y6AQTuUQ}6\
Itbc4 sIN$#f
1b[AvS#† E VLV(?R +N5
Itbc4 sIN$#f
H
y6AQTuUQ}6\
Itbc4 sIN$#f
3I:gX^O† W UH~, f CnC S}\n
Itbc4 sIN$#f
H
y6AQTuUQ}6\
Itbc4 sIN$#f
wzw8wI:ss F Z|3d Z poTXX ^=^M
Itbc4 sIN$#f
H
y6AQTuUQ}6\
Itbc4 sIN$#f
vEv|v?rrP c -oU] - C}T]K 4J+$
Itbc4 sIN$#f
H
y6AQTuUQ}6\
Itbc4 sIN$#f
i*io50_+ H 6^8~2 @xvRxQq
Itbc4 sIN$#f
H
y6AQTuUQ}6\
Itbc4 sIN$#f
Bcq~$pp c N~k qpG
Itbc4 sIN$#f
H
y6AQTuUQ}6\
Itbc4 sIN$#f
Qd2|:!Qd{!@⁷ q y?7!B` ( |xA j8??
~_s5_
H
y6AQTuUQ}6\
~_s5_
yy55y0y1y^⁶ A ?KKC A Cls Ia?%
KE 5~J~
M
y6AQTuUQ}6\
KE 5~J~
ZJ qV|VPlP
M
y6AQTuUQ}6\
ZJ qV|VPlP
0M=Mu0u
M
y6AQTuUQ}6\
0M=Mu0u
XD }^l^
0
y6AQTuUQ}6\
XD }^l^
/#AA=#hAP t 91Z9 {u1 qd(qZqO+x
U5 L_+ IzC$iQ F@S;
M
y6AQTuUQ}6\
U5 L_+ IzC$iQ F@S;
vwvxzva** + NN?? +|u
Itbc4 sIN$#f
H
y6AQTuUQ}6\
Itbc4 sIN$#f
JIJT7Df}7 d vp9ζ jznjujrIY
Itbc4 sIN$#f
H
y6AQTuUQ}6\
Itbc4 sIN$#f
ljly*JD1J ^ n:40 @V@z|V:
Itbc4 sIN$#f
H
y6AQTuUQ}6\
Itbc4 sIN$#f
w]w3ots)s 6 P8Tf :Z/:W:75e
Itbc4 sIN$#f
H
y6AQTuUQ}6\
Itbc4 sIN$#f
G^wJCIJUIwIC { *%` -^Q-g-)]S
SQQ%=QQ
M
y6AQTuUQ}6\
SQQ%=QQ
fk
M
y6AQTuUQ}6\
fk
u,u c~
M
y6AQTuUQ}6\
u,u c~
=n= ro$
M
y6AQTuUQ}6\
=n= ro$
!f LoQ
M
y6AQTuUQ}6\
!f LoQ
:[: {2~
0
y6AQTuUQ}6\
:[: {2~
gGg ya;3a ?Ue[ CEhqY
0
y6AQTuUQ}6\
gGg ya;3a ?Ue[ CEhqY
=|mz{]_`h5 A1W3AWS r5$:33 `[UEnq[qZExk
0
y6AQTuUQ}6\
=|mz{]_`h5 A1W3AWS r5$:33 `[UEnq[qZExk
QLftLALy&w@ W za35 C:vC=CK96
-k {BBᵃ
M
y6AQTuUQ}6\
-k {BBᵃ
*J* HC
0
y6AQTuUQ}6\
*J* HC
U0U WOO
0
y6AQTuUQ}6\
U0U WOO
:[: {2~
0
y6AQTuUQ}6\
:[: {2~
P\ 2oov]oo†
0
y6AQTuUQ}6\
P\ 2oov]oo†
2p2 ,, ZISH l\^^9^_s
H
y6AQTuUQ}6\
2p2 ,, ZISH l\^^9^_s
seeXe@S
H
y6AQTuUQ}6\
seeXe@S
16#}44 ,eV+Hzezu+=h
H
y6AQTuUQ}6\
16#}44 ,eV+Hzezu+=h
WhW(a22i_ g !r# TwhT
16#}44 ,eV+Hzezu+=h
H
y6AQTuUQ}6\
16#}44 ,eV+Hzezu+=h
efOBEE p?jM?P?PoM2F†
H
y6AQTuUQ}6\
efOBEE p?jM?P?PoM2F†
c/c yvQ {-k zVz cjj
0
y6AQTuUQ}6\
c/c yvQ {-k zVz cjj
^M^i1T00` = t^G/ {!y ?jk6 k1`k)k\`V
16#}44 ,eV+Hzezu+=h
H
y6AQTuUQ}6\
16#}44 ,eV+Hzezu+=h
F8P]}]85RiZ6 @ @4Gt Otj
c9c =t%
M
y6AQTuUQ}6\
c9c =t%
WB3fLcr3i&Y V 47}74 $00
j^j 8P~;P
H
y6AQTuUQ}6\
j^j 8P~;P
G^wJCIJUIwIC { *%` -^Q-g-)]S
W%wrt%! *e*_;Jewr* ]R{PEl{ORP:
M
y6AQTuUQ}6\
W%wrt%! *e*_;Jewr* ]R{PEl{ORP:
oGhGV PBf&REXE+
0
y6AQTuUQ}6\
oGhGV PBf&REXE+
RfR2^NrlN ? (`tq; Gr7G
uppXxLtL+s c?sz% ?\mD(66(}?u\
H
y6AQTuUQ}6\
uppXxLtL+s c?sz% ?\mD(66(}?u\
9muCNHLv1vNu¹ E 2Dv { q2{? v\Rh
cNW!:V4!Z WgW ^1!{DD
0
y6AQTuUQ}6\
cNW!:V4!Z WgW ^1!{DD
F8P]}]85RiZ6 @ @4Gt Otj
;t :Jw@D tqEyE
M
y6AQTuUQ}6\
;t :Jw@D tqEyE
BS QI ouQ%Q
M
y6AQTuUQ}6\
BS QI ouQ%Q
5D;x CaQsQ
M
y6AQTuUQ}6\
5D;x CaQsQ
?v}Yr~j V_TRT
M
y6AQTuUQ}6\
?v}Yr~j V_TRT
ZJ qV|VPlP
M
y6AQTuUQ}6\
ZJ qV|VPlP
X2 $244
M
y6AQTuUQ}6\
X2 $244
$i )1EE
M
y6AQTuUQ}6\
$i )1EE
Kf Ivll
M
y6AQTuUQ}6\
Kf Ivll
w9 ~N|~exN
M
y6AQTuUQ}6\
w9 ~N|~exN
wd L8O
M
y6AQTuUQ}6\
wd L8O
)E 7UU
M
y6AQTuUQ}6\
)E 7UU
Zz Cas
M
y6AQTuUQ}6\
Zz Cas
h~_? `((
0
y6AQTuUQ}6\
h~_? `((
|j )eB}B zaR!-RUP@AORa u@_N`odv6@Pw
H
y6AQTuUQ}6\
|j )eB}B zaR!-RUP@AORa u@_N`odv6@Pw
WB3fLcr3i&Y V 47}74 $00
}# iP3ch -0k- 6}!J!
M
y6AQTuUQ}6\
}# iP3ch -0k- 6}!J!
;M]H] Pu&V *d1H;\VcM;d1
H
y6AQTuUQ}6\
;M]H] Pu&V *d1H;\VcM;d1
SuJnKto*² f ehGO Ss1SJSOIO
d7 %iJ oK8c! E^J/eG
H
y6AQTuUQ}6\
d7 %iJ oK8c! E^J/eG
pppDK55@a T Q]{0 A|1A|A^0T
d7 %iJ oK8c! E^J/eG
H
y6AQTuUQ}6\
d7 %iJ oK8c! E^J/eG
E=;tG=++³ Q V8!d B:X
d7 %iJ oK8c! E^J/eG
H
y6AQTuUQ}6\
d7 %iJ oK8c! E^J/eG
WWW(\`5h h /^HV 2%;
Itbc4 sIN$#f
H
y6AQTuUQ}6\
Itbc4 sIN$#f
hShM77^⁴ # 4l2% IgD
eJJaMQM
0
y6AQTuUQ}6\
eJJaMQM
X2 $244
0
y6AQTuUQ}6\
X2 $244
\%2CWooPᵇ : r8 %}?{m`u`m}`6
bC #,JZJ
0
y6AQTuUQ}6\
bC #,JZJ
?v}Yr~j V_TRT
0
y6AQTuUQ}6\
?v}Yr~j V_TRT
o3F D_r&r
0
y6AQTuUQ}6\
o3F D_r&r
eg 3XFee
0
y6AQTuUQ}6\
eg 3XFee
b{mUf{u{f{b⁵ k fy-5 pal(
ZB @K&r0 W@`
0
y6AQTuUQ}6\
ZB @K&r0 W@`
Az DTPSw F3L
M
y6AQTuUQ}6\
Az DTPSw F3L
rfr8zHHR w 1Snx Xe;
T:$3t8S3f 6i
0
y6AQTuUQ}6\
T:$3t8S3f 6i
T[TLliOyi & XtoK )5K)\)(Z?
Itbc4 sIN$#f
H
y6AQTuUQ}6\
Itbc4 sIN$#f

n~ r9 O)rch%c+ {#{`

HAmgen collaboration; BeiGene has China commercial rights. 0Ensem collaboration; BeiGene has global rights. MDualityBio collaboration; BeiGene has global clinical, manufacturing, and commercialization rights. yLeads Biolabs collaboration; BeiGene has global research, development, and manufacturing rights, and exclusive commercialization rights outside of China. YZymeworks/Jazz collaboration; BeiGene has exclusive development and commercialization rights in Asia (except Japan), Australia, and New Zealand. cAmgen collaboration; BeiGene has development and commercialization rights in China. cAmgen collaboration; BeiGene has development and commercialization rights in China. QIn combination with Zanubrutinib. =May include: PD-1 mAb, LAG3 mAb, OX40 mAb, TIM3 mAb, HPK1 inhibitor. † Trial is listed on clinicaltrials.gov, but may not have subjects enrolled.

Please login or register for full access

Register

Already registered?  Login